Draig Therapeutics

About Draig Therapeutics

Draig Therapeutics is dedicated to delivering next-generation treatments for neuropsychiatric disorders by developing highly targeted neuromodulators. Their mission is to redefine treatment paradigms and enable individuals with neuropsychiatric disorders to live their best lives.

Products & Services

DT-101:A next-generation AMPA receptor positive allosteric modulator (PAM) aimed at becoming a transformative treatment for Major Depressive Disorder (MDD). It is set to enter Phase 2 trials in 2025.

GABAA Receptor Modulators:Highly selective modulators with strong therapeutic potential for a range of prevalent and underserved neuropsychiatric disorders, advancing towards clinical development.

Specialties

Neuropsychiatric Drug Development Neuromodulators Glutamate and GABA Modulation Major Depressive Disorder (MDD) Treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 140000000 MR: - FA: $140 million FAN: 140000000	D: 2025-06-18 FD: 2025-06-18	7 investors

Series A Latest

2025-06-18

$140.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Atack

Chief Translational Officer & Founder

LinkedIn (Pro only)

S

Simon Ward

Chief Scientific Officer & Founder

LinkedIn (Pro only)

R

Ruth McKernan

British Neuroscientist

LinkedIn (Pro only)

D

David Watson

Chief Operating Officer

I

Inder Kaul

Chief Medical Officer

F

Florian Islinger

Chief Commercial Strategy Officer

View 19 more team members with Pro

Unlock Full Team Directory

Recent News